Shenzhen Taili Biomedicine Co., Ltd.

(1) Evaluate and compare the pharmacokinetic characteristics of a single oral dose of NF2105 capsules (fasting) and nilotinib capsules (low-fat modified fasting) in healthy subjects; (2) Evaluate the relative bioavailability of a single oral dose of NF2105 capsules (fasting) and nilotinib capsules (low-fat modified fasting) in healthy subjects; (3) Assess the safety of a single oral dose of NF2105 capsules (fasting) and nilotinib capsules (low-fat modified fasting) in healthy subjects.

(1) To evaluate the relative bioavailability of NF2105 capsules and nilotinib capsules in healthy subjects after a single fasting oral administration; (2) To evaluate the pharmacokinetic characteristics of NF2105 capsules and nilotinib capsules in healthy subjects after a single fasting oral administration; (3) To assess the safety of NF2105 capsules and nilotinib capsules in healthy subjects after a single fasting oral administration.

(1) Evaluate and compare the pharmacokinetic characteristics of single oral administration of NF2105 capsules (fasting/postprandial) and nilotinib capsules (fasting/modified fasting) in healthy subjects; (2) Evaluate the effect of a high-fat diet on the pharmacokinetics of single oral administration of NF2105 capsules and nilotinib capsules (modified fasting) in healthy subjects; (3) Evaluate the relative bioavailability of single oral administration of NF2105 capsules and the original nilotinib capsules in healthy subjects (fasting/postprandial); (4) Assess the safety of single oral administration of NF2105 capsules (fasting/postprandial) and nilotinib capsules (fasting/modified fasting) in healthy subjects.